Right ventricular failure (RVF) is the main determinant of mortality in patients with pulmonary arterial hypertension (PAH). Although the exact pathophysiology underlying RVF remains unclear, inflammation may play an important role, as it does in left heart failure. Perivascular pulmonary artery and systemic inflammation is relatively well studied and known to contribute to the initiation and maintenance of the pulmonary vascular insult in PAH. However, less attention has been paid to the role of cardiac inflammation in RVF and PAH. Consistent with many other types of heart failure, cardiac inflammation, triggered by systemic and local stressors, has been shown in RVF patients as well as in RVF animal models. RV inflammation likely contributes to impaired RV contractility, maladaptive remodelling and a vicious circle between RV and pulmonary vascular injury. Although the potential to improve RV function through anti-inflammatory therapy has not been tested, this approach has been applied clinically in left ventricular failure patients, with variable success. Because inflammation plays a dual role in the development of both pulmonary vascular pathology and RVF, anti-inflammatory therapies may have a potential double benefit in patients with PAH and associated RVF.
Introduction
Pulmonary arterial hypertension (PAH) is a fatal disease characterized by pulmonary vascular remodelling and a chronic and frequently progressive increase in right ventricle (RV) afterload, eventually leading to RV failure (RVF) and premature death. Although the initial insult in PAH involves the pulmonary vasculature, RVF is the most important determinant of mortality in patients with PAH. 1 Many questions, however, regarding the mechanisms underlying RVF remain unclear. In recent years, multiple studies have focused on the evidence of inflammation in PAH, and highlighted the role of inflammation in the initiation and maintenance of pulmonary vascular remodelling. [2] [3] [4] Accumulation of perivascular inflammatory cells as well as systemic overabundance of pro-inflammatory cytokines and chemokines have been observed in clinical and experimental PAH, and have been proposed to contribute to the process of pulmonary vascular remodelling. 2, 3, 5, 6 However, compared with the pulmonary vasculature, the role of inflammation in the transition from RV adaptation to failure is less well known. Intriguingly, evidence of RV inflammation has been found in patients with acute pulmonary embolism (PE) related RVF and in patients with HIV and systemic sclerosis associated PAH (SSc-PAH). [7] [8] [9] Moreover, cardiac inflammation has been demonstrated in several experimental RVF models, with increased infiltration of inflammatory cells and expression of multiple cytokines and chemokines, which are related to the progression of RVF. 10, 11 Evidence of inflammatory responses in the heart of patients with many types of cardiovascular diseases other than PAH has been accumulating for decades. [12] [13] [14] Inflammation is considered a double-edged sword,
as it stimulates the immune response to microbial infection while it may also lead to further injuries in non-infectious conditions, such as cardiovascular diseases. 12 The 'Cytokine Hypothesis' is regarded as one of the basic mechanisms for the development of heart failure (HF), and states that a cardiac event triggers systemic activation of pro-inflammatory cytokines, which in turn accelerate the progression of HF. 15 Indeed, increased levels of circulating inflammatory cytokines have been found associated with the New York Heart Association (NYHA) functional class in HF patients. 16 
Potential inflammatory triggers in RVF: wall stress, ischaemia, systemic inflammation and neurohormonal activation
Due to the multifactorial nature of PAH, it is difficult to pinpoint an initial trigger of RV inflammation. We propose that both local stressors and systemic influences could promote a 'pro-inflammatory environment' in the overloaded RV. Potential local triggers of cardiac inflammation include mechanical stress and ischaemia, while systemic influences likely consist of increased circulating levels of proinflammatory cytokines and activated immune cells and neurohormonal activation. Both in vitro and in vivo studies have suggested that mechanical stress can directly initiate cardiac inflammation through the local production of reactive oxygen species (ROS) and secondary activation of nuclear factor-rB (NF-rB). [17] [18] [19] Ten minutes of mechanical stretch in adult feline cardiomyocytes can induce myocardial overexpression of proinflammatory cytokines such as tumour necrosis factor-a (TNF-a), which is followed by leukocyte infiltration. 17 In vivo, aortic banding can increase the level of TNF-a, interleukin-6 (IL-6), C-C motif chemokine ligand 2 (CCL2), CCL3, and inflammatory cell accumulation in the left ventricle (LV). 20 In the rat model of experimental pulmonary hypertension (PH)
induced by monocrotaline (MCT), RV inflammation was not found in stable PH but in progressive PH, the latter being associated with a larger RV end-diastolic diameter indicating a higher RV wall stress. In addition, exercise was observed to increase RV inflammation in progressive PH, which is related to increased RV wall stress during episodes of activity, also suggesting that high RV wall stress might be an explanation for RV inflammation. 21 These studies are not entirely conclusive, however, because of the direct pro-inflammatory properties of MCT administration. 22 ,23 Figure 1 The role of inflammation in the vicious circle between pulmonary vascular remodelling and right ventricular failure. In PAH, perivascular inflammation plays a role in pulmonary vascular remodelling, which leads to increased RV mechanical stress, ischaemia, and increased inflammation in systemic circulation, triggering RV inflammation. Increased activity of neurohormonal system is also a trigger of RV inflammation. While RV inflammation may lead to the progression of RVF, the failing heart will further increase neurohormonal activity, which promotes pulmonary vascular remodelling. Altogether, a vicious circle is formed between RV inflammation, RVF, and pulmonary vascular remodelling. PAH, pulmonary arterial hypertension; RVF, right ventricular failure. In addition to mechanical stress, ischaemia is another known trigger of the expression of inflammatory cytokines in the heart. [24] [25] [26] [27] Although the normal RV is less susceptible to infarction, 28 the pressure overloaded RV is more susceptible to ischaemia than the pressure overloaded LV, because of a diminished RV coronary flow reserve, a greater systolic-diastolic coronary flow ratio, and an impaired angiogenic response to increased afterload. 29 Therefore, RV ischaemia due to a decrease in capillary density and right coronary artery perfusion impairment may explain the findings of RV inflammation in experimental PHA 30, 31 as well as in SScPAH patients, who are known to have functional abnormalities of the small coronary arteries. 32 Spill-over of pulmonary vascular inflammation into the systemic circulation may lead to increased serum levels of inflammatory cytokines in PAH, which are not only biomarkers that can be used for risk stratification of PAH patients, 33 but may also directly affect RV function.
Inflammatory cells may be activated in the lung and subsequently invade the RV. However, because only few inflammatory cells can be observed infiltrating the RV from iPAH patients (alike experimental RVF models; Table 1 ), it is doubtful whether systemic inflammation plays a role in RV inflammatory responses. It is more likely that local stresses together with neurohormonal overdrive play crucial roles in this process. Increased activity of neurohormonal system, particularly the reninangiotensin (Ang)-aldosterone system and the neuro-adrenergic system, 34, 35 is a second systemic aspect of PAH well capable of triggering inflammation both in the pulmonary vasculature and in the heart. 36, 37 During HF development, increased activity of the sympathetic nervous system contributes to increased cardiac inflammation, including upregulated expression of TNF-a and IL-1b. 38 Treatment with the selective b-blocker bisoprolol improved cardiac function as well as reduced RV inflammation in experimental PH rats. 39 Both Angiotensin II (AngII) and cytokines are promotors of endothelin-1 (ET-1) expression, [40] [41] [42] [43] and ET-1 can increase the expression of cardiac pro-inflammatory cytokines and neurohormonal activation. [44] [45] [46] Moreover, cardiac inducible nitric oxide synthase (iNOS) expression can be increased by cytokines such as TNF-a and IL-1, which causes further calcium and mitochondrial dysfunction, as well as additional disruption of the neuro-adrenergic system. [47] [48] [49] Altogether, while cardiac inflammation may contribute to the progression of RVF, the failing heart will further promote sympathetic overdrive, creating a vicious circle between RV inflammation, and RVF and pulmonary vascular remodelling ( Figure 1 ).
Evidence of cardiac inflammation in RVF

Inflammatory cell recruitment into the failing RV
Presence of multiple leukocytes, cytokines and chemokines has been studied in the failing RV. A recent study of biventricular biopsies from 15 patients with HIV-associated PAH found lymphocytic myocarditis in 12 patients, microvasculitis in 3 of these patients, and increased endothelial cell (EC) adhesion molecules in all 15 patients, including vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), E-selectin and human leukocyte antigen-antigen D related (HLA-DR). 50 Also the study of heart tissues from SSc-PAH patients revealed inflammation in RV tissues. SSc is a disease with a multifaceted pathology, characterized by an enhanced inflammatory status, vasculopathy and excessive fibrosis in skin and internal organs. PAH induced RVF is the leading cause of death in SSc patients. 51 Compared with idiopathic PAH (IPAH) patients, SSc-PAH patients have a worse RV function and prognosis, even though the pulmonary vascular resistance is similar. 52, 53 By analysing the heart tissues from 5 SSc-PAH patients, Overbeek et al.
found significantly more leukocytes in the RV tissues compared with normal controls as well as compared with the RV from IPAH patients, including increased number of lymphocytes, macrophages and neutrophilic granulocytes, suggesting that inflammation may contribute to a worse RV function in SSc-PAH patients. 9 In contrast, the authors found no significant inflammatory cell infiltration increase in RV tissues from 9 patients who died from IPAH compared to control, though there is a tendency towards increased neutrophils and lymphocytes. 9 This finding was confirmed by Begieneman et al. who compared the number of lymphocytes, macrophages and neutrophilic granulocytes in RV tissues between 11 patients who died of IPAH compared to controls ( Table 2) .
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Studies on RV inflammation in PAH are limited by a small sample size and by the fact that only RV tissues from patients with end-stage disease were available. It is possible that inflammation is no longer present or active in end-stage RVF, but heavily involved in the transition from RV adaptation to failure. In addition, even though the quantity of inflammatory cells is low in the RV from IPAH patients, their functional effects may still be important on the progression of the disease ( Figure 2 ).
Experimental RVF: inflammatory cell influx and altered expression of cytokines
Important evidence that inflammation does play a role in the progression of RV failure comes from studies of experimental RVF. Several animal models have been used to investigate the pathogenesis of PH and PHinduced RVF, such as MCT induced PH, pulmonary artery banding (PAB), angioproliferative disease due to blockade of vascular endothelial growth factor receptor antibody blocker (SU5416) plus chronic hypoxia (SuHx) and systemic to pulmonary shunt models. [54] [55] [56] Though it is clear that there is no perfect experimental model of human PAH currently available, these models have provided valuable contributions to the understanding of PAH.
MCT. MCT is a plant-derived alkaloid that induces pulmonary EC injury and perivascular inflammation. 54 A single subcutaneous injection of 40 mg/kg MCT induces stable PH with a preserved cardiac output (CO) in rats after 2 weeks, while 60 mg/kg MCT induces progressive PH developing RVF. 21 Multiple studies have shown that RV inflammation is increased in progressive MCT induced PH, including leukocyte infiltration, 21 ,39 neutrophil activation, 10,57 increased expression of proinflammatory cytokines including TNF-a, 10,57-61 TNF-like weak inducer of apoptosis (TWEAK), 59 IL-1b, 60 and IL-6. 62 Moreover, inflammatory activation in the RV of MCT rats is characterized by a specific time course, showing an early increase which peaks at the stage of RV dilation, and continues into the RVF stage. 10, 62 Among the pro-inflammatory cytokine pathways, TNF superfamily signalling appears to be involved in the pathogenesis of RVF via the non-canonical NF-rB pathway, with increasing expression of NF-rB subunits p100/p52 and Rel-B. 59 On the other hand, no inflammatory changes have been found in stable MCT induced PH. 21, 63 Collectively, these data suggest a possible association between RV inflammatory activation and early stages of RVF. PAB. Mice develop RVF one week after the PAB operation. Several chemokines have been found upregulated in the RV in this model, including CCL2, CCL5, C-X-C motif ligand 6 (CXCL6), CXCL10, C-X3-C motif ligand 1 (CX3CL1), and CXCL16. Among these chemokines, CXCL16, CX3CL1, and CCL5 may play a role in RV remodelling via enhancing small leucine-rich proteoglycans (SLRPs). 64 Meanwhile, leukocyte infiltration was also increased in the RV, including both CD4 þ and CD8 þ T cells, while no chemokine or leukocytes increase was found in the LV. 64 The expression of TWEAK receptor fibroblast growth factorinducible 14 (Fn14) is also increased in the RV from PAB mice. 65 TWEAK belongs to the TNF superfamily and TWEAK levels are inversely correlated with the severity of PAH in patients. 66 In another chronic PAB-induced RVF model in rats, elevated expression of activated NF-rB and increased numbers of CD68-positive macrophages were found in RV tissues. Chronic treatment with the NF-rB inhibitor pyrrolidinedithiocarbamate reversed RV inflammation and fibrosis, as well as improved RV function after PAB. 67 Aortic-pulmonary shunt. Aortic-pulmonary shunting in growing piglets is a recognized model of congenital left-to-right shunt-induced PH. 11 While the piglets develop PH with preserved RV function with 3 months of shunting, more prolonged shunting can induce pronounced RVF, with elevated serum TNF-a levels and increased cardiac expression of proinflammatory cytokines. 11 The expressions of IL-1a and IL-1b were increased in both the RV and LV of shunted piglets, while TNF-a and ICAM-2 expressions were only increased in the RV. No changes were found in IL-6, IL-10, IL-19, IL-33, suppression of tumorigenicity 2 (ST2), ICAM-1, VCAM-1, or signal transducer and activator of transcription 3. 11,68 The fact that expressions of cytokines are increased in the LV may indicate the progression towards global HF. In addition, a negative correlation was found between RV ICAM-2 gene expression and RVpulmonary artery coupling as shown by end systolic elastance/arterial elastance (Ees/Ea). 68 Others. In SuHx induced PAH rats, the gene expression of IL-6 and CCL-2 in RV tissues had a tendency to be up-regulated, but differences are not significant. 69 However, female ovariectomized SuHx rats were found to develop severe RV dysfunction and significantly up-regulated gene expression of IL-6 and CCL-2 in the RV. 69 In a tetralogy of Fallot model by transvalvular patch inducing RV tract enlargement together with PAB in piglets, even though RVF was established with significant fibrosis and myocardial hypertrophy, cardiac inflammation was not observed. 70 
Cardiac inflammation in RVF related to other diseases
The presence of acute RVF following PE is a strong predictor of poor clinical outcome. 71 In a rat model of PE induced by microspheres injection via the right jugular vein, massive accumulation of neutrophils and monocyte/macrophage was found in the RV, as well as increased chemokine expression, including CCL2, cytokine-induced neutrophil chemoattractant-1 (CINC-1), CINC-2, CXCL2, and CCL3. 75 Moreover, suppression of the inflammatory response by the anti-inflammatory agent ketorolac sodium improved survival in this PE model, while antibodies targeted at neutrophil or chemoattractants, such as polymorphonuclear leukocytes and CINC-1, reduced neutrophil accumulation and activity, limited RV damage and prevented RVF. [75] [76] [77] RVF due to a pulmonary hypertensive crisis can be experimentally reproduced in animals by transient PAB. 78 In a dog model with 90-minute PAB, persistent RVF was found to be associated with increased RV expression of TNF-a, IL-1b, IL-6, IL-6/IL-10 ratio, CCL2, VCAM-1, neutrophil and macrophage infiltration, as well as decreased IL-10 and IL-33. 78, 79 After establishment of RVF in pigs after 2 h of PAB, microarray analysis showed that nine inflammation related genes were up-regulated in RV tissues, including IL-6, IL-8, pentraxin 3, CCL2, CXCL6 and CXCL2. 80 RVF is the leading cause of early death after cardiac transplantation, and RV inflammation was found significantly increased in experimental brain death-induced RVF, including IL-1b, IL-6, IL-10, TNF-a, ICAM-1, ICAM-2, and VCAM-1, whereas IL-33 expression was decreased. 81 By analysing 26 donor RV biopsies, TNF-a expression was found to be a predictor for the development of RVF in patients early after transplantation. 86 These effects have also been confirmed in vivo, for example, as leukocyte dependent decreased contractility in animal models of left ventricular failure (LVF). 87, 88 In transverse aortic constriction (TAC) mice model, impaired LV contractility has been found to be associated with T cell infiltration, while LV contractility is preserved in T cell deficient mice and anti-CD3 pre-treated mice. 89, 90 Among the pro-inflammatory cytokines, TNF-a contributes to contractile dysfunction by inducing b-adrenergic receptor uncoupling, ROS formation and iNOS expression, and by decreasing contractile proteins in cardiomyocytes. 91, 92 A study in rats showed that circulating concentrations of TNF-a similar to HF patients are sufficient to cause persistent negative inotropic effects and are reversible after stopping TNF-a infusion. 91 In a recent study with MCT induced PH rats, TNF-a overexpression in RV was significantly correlated with the downregulation of sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) 2a expression and overexpression of phospholamban, which contributes to calcium overload. 58 Moreover, microRNA 208 (miR208) inhibition together with increased TNF-a as a 'second hit' was found to contribute to the transition from compensated RV hypertrophy to RVF, with decreased CO and RV contractility. 93 Various studies have revealed a link between IL-1b and impaired contractility, mainly due to L-type calcium channel inhibition and b-adrenergic receptor desensitization. 94, 95 In addition, IL-1b can increase NO activity by increasing iNOS expression, which can further disrupt calcium channels, b-adrenergic receptor signalling and mitochondrial function, contributing to impaired contractility. 48, 49, 96 IL-1b also changes the expression of the calcium handling proteins phospholamban and SERCA in cardiomyocytes.
97 Figure 2 Recruitment of inflammatory cells into the failing right ventricle. Recruitment of inflammatory cells into the failing RV is attributed to the direct effect of neurohormonal changes and increased cytokines production. Neurohormonal overdrive can directly promote cardiac macrophage recruitment. Circulating cytokines generated within a 'sick lung' circulation contribute to cardiac insulin resistance, which induces NF-RB activation in cardiomyocytes. Mechanical stress can induce NF-RB activation in cardiomyocytes by producing ROS. Ischaemia can stimulate cardiomyocytes to release DAMPs, which activate NF-RB through binding to TLR4. The activation of NF-RB in cardiomyocytes leads to the expression of a wide range of pro-inflammatory cytokines that promote the recruitment of inflammatory cells into the RV. In addition, increased ET-1 from the lung contributes to cytokine production of both cardiomyocytes and ECs. The cytokines TNF-a and IL-1 may induce fibroblast production of other pro-inflammatory cytokines and chemokines, which further increase the recruitment of inflammatory cells into the RV. TLR4, Toll-like receptor 4; DAMPs, damage-associated molecular patterns. The effects of IL-6 on myocardial contractility are well documented both in vitro and in vivo. IL-6 not only has a direct inotropic effect on isolated papillary muscle and reduces SERCA in isolated cardiomyocytes, 98 but also reduces the expression of a-myosin heavy chain, b-myosin heavy chain and cardiac actin. 91 In vivo, subcutaneous administration of IL-6 to rats can lead to a dose-dependent deterioration of cardiac contractility. 99 In contrast, IL-33/ST2 signalling may have a cardioprotective role via the fibroblast-cardiomyocyte paracrine system. 100 In the heart, IL-33 is synthesized by cardiac fibroblasts while its receptors ST2L and soluble ST2 (sST2) are both biomechanically induced in cardiomyocytes. 100, 101 In the failing RV of dogs subjected to transient PAB, the expression of IL-33 was decreased and a correlation was found between Ees/Ea ratio and RV gene expression of IL-33, suggesting a protective role of IL-33 in RV contractility. 78 Intriguingly, patients with HF show elevated sST2 especially in the presence of PH and RV dysfunction, and sST2 levels carry a strong prognostic value. 102, 103 Moreover, serum sST2 is increased in PAH patients, and its level is strictly related to the degree of RV dilatation and systolic dysfunction. 104 In the recent RELAX trial, performed in 174 patients with HF with preserved ejection fraction (HFpEF), no associations were found between sST2 levels and LV function, but higher sST2 levels were significantly associated with higher RV systolic pressure and impaired RV contractility. 105 Based on the cardioprotective role of IL-33/ST2 pathway, it is likely that sST2 binds to IL-33, decreasing its tissue availability and thus blocking cardioprotective effects through ST2L.
Inflammation and myocardial hypertrophy, apoptosis and fibrosis
Pro-inflammatory cytokines and leukocytes contribute to heart remodelling by inducing myocardial hypertrophy, apoptosis, and fibrosis. Several studies have revealed the effect of macrophages to induce cardiac hypertrophy in HF models through various mechanisms, involving miR55 and activating transcription factor 3. 106,107 By inducing the reexpression of foetal genes and downregulating the calcium homeostasis genes, IL-1b can cause hypertrophy of neonatal rat cardiomyocytes in vitro. 108 IL-6 family signalling induces gene expression in the cardiomyocytes that is associated with pathological hypertrophy. 109 TNF-a can induce myocardial hypertrophy in vitro, 110, 111 as well as induce LV hypertrophy and dilation in vivo. 112 In addition, TWEAK and its receptor Fn14 are involved in pathological cardiac hypertrophy and promote myocardial hypertrophy in vitro. 113 Transgenic overexpression of full length-TWEAK in mice resulted in dilated cardiomyopathy with myocardial hypertrophy. 114 In PAB induced RVF mice, Fn14 deletion attenuated RV hypertrophy. 113 TNF-a can trigger apoptosis in many cell types, including cardiomyocytes. 115, 116 This effect was not only demonstrated in vitro, but also in dogs with LVF. 92 Moreover, TNF-a can increase cardiac fibrosis through activating matrix metalloproteinase (MMP) and downregulating tissue inhibitor of MMP in a ROS dependent way. [117] [118] [119] In vivo, TNF-knockout mice with aortic banding showed attenuated apoptosis, hypertrophy, and fibrosis, with improved cardiac function. 20 TNF-a increases the expression of other inflammatory cytokines such as IL-1 and IL-6, thus further impairing cardiac function. 20 However, it has to be mentioned that TNF-a has a more complex role in cardiac remodelling and function.
Further research on selective tumour necrosis factor-receptor (TNFR) knockout mice indicates that the effects of TNF on inflammatory and ventricular remodelling are receptor specific. TNFR1 exacerbates the inflammatory response, myocardial hypertrophy, apoptosis, and fibrosis, whereas TNFR2 ameliorates these events. 120 Finally, TWEAK/Fn14 has also been found to be implicated in processes of cardiac fibrosis. 114, 121 In PAB induced RVF mice, Fn14 deletion reduced RV fibrosis. 65 While multiple studies on fibrosis of the pressure-overloaded myocardium have focused on the role of macrophages as driving cell type, 122,123 recent studies have revealed a crucial role of lymphocytes in cardiac remodelling. In TAC induced LVF mice, LV fibrosis can be prevented in mice deficient in mature CD4 þ T cells, although cardiac hypertrophy can still be observed. 90 Further studies using the TAC model revealed markedly decreased LV hypertrophy and fibrosis in T cell deficient mice or anti-CD3 antibody treated wild-type mice. 89 In addition, a study using the AngII infusion model of hypertensive cardiac remodelling revealed a crucial role of CD8 þ cells in perivascular and interstitial fibrosis via recruitment and activation of macrophages. 124 Chemokines such as CXCL16 and CCL5 contribute to RV fibrosis after PAB by modulating the expression of SLRP in cardiac fibroblasts, which are known as fibrosis regulators. 64 Besides, the cardiomyocytesmacrophages cross talk mediated by the interferon !-CXCL10-CXCR 3 axis also contributes to cardiac fibrosis. 125 In contrast, as a potent immunomodulatory that inhibits various proinflammatory cytokines, 126 adeno viral expression of IL-10 protects against MCT induced PH in rats with decreased pulmonary vascular remodelling and RV hypertrophy. 127 Aerobic exercise at an early stage has cardioprotective effects in MCT induced PH rats, partly by decreasing TNF-a/IL-10 ratio. 61 IL-33 was found to reduce AngII and phenylephrine induced hypertrophy of cardiomyocytes in vitro. 100 Targeted deletion of ST2 in mice led to marked hypertrophy and fibrosis following pressure overload, while treatment of WT mice with purified recombinant IL-33 protected the myocardium but not in ST -/-mice, revealing IL-33/ST2 signalling as a crucial cardioprotective fibroblast-cardiomyocyte paracrine system. Cardiac fibroblasts play important roles as sensors and amplifiers of signals from immune cells and cardiomyocytes, by secretion of cytokines, growth factors, and chemokines. 128 Both TNF-a and IL-1 can increase fibroblast migration and induce fibroblast production of other pro-inflammatory cytokines (e.g. IL-6) and chemokines (e.g. CXCL-1, -2, -5, -8). 129, 130 While TNF-a can increase cardiac fibroblast proliferation, IL-1 was shown to inhibit it. [131] [132] [133] In addition, IL-1 can activate the expression of transforming growth factor b (TGF-b), which is the major profibrotic cytokine that induces differentiation of fibroblasts into myofibroblasts and the generation of extracellular matrix proteins. 134, 135 In addition, macrophages play an important role in the differentiation of fibroblast into myofibroblasts via expression of TGF-b.
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Capillary rarefaction
Capillary rarefaction is an additional cause of RV ischaemia besides decreased coronary perfusion. Capillary rarefaction has been found in the RV from SuHx and MCT rats, but not in the RV of rats subjected to pulmonary artery banding. 30, 138, 139 Capillary rarefaction may also occur in PAH patients, particularly in patients with ssc-PAH. 138 It has been recognized that impaired angiogenesis and microvascular EC injury contribute to capillary rarefaction, in particular downregulation of VEGF signalling and microRNA 126. 140 Anti-endothelial cell antibodies (AECAs) have been detected in the serum of patients with IPAH or with SSc-PAH or with SSc without PAH. 141, 142 The identified target antigens include lamin A/C, tubulin bchain and vinculin, which are implicated in cell morphology, metabolism and protein folding in various cell types. 143 Indeed, ACEAs have been found to activate EC and induce EC apoptosis and therefore play a role in the pathogenesis of EC damage and vasculitis. [144] [145] [146] IgG from ACEApositive PAH patients has been found to induce inflammatory response on EC. 147 Even though there is no direct evidence indicating the role of AECAs on RV capillary density, their presence in PAH patient serum suggests a potential role. Indeed in SSc patients, a correlation was found between the detection of ACEAs and the development of severe digital ischaemia and PAH. 148 However, the role of AECAs on RV capillary rarefaction during PAH needs to be further studied.
Immunometabolism
Pro-inflammatory cytokines have been found to promote systemic insulin resistance and contribute to cardiac insulin resistance. [149] [150] [151] Moreover, exposure of fatty acids or high glucose can induce NF-RB activation in cardiomyocytes, which in turn increases the production of pro-inflammatory cytokines. 152, 153 In metabolic cardiomyopathy, inflammation and insulin resistance in adipose tissue induce systemic inflammation and insulin resistance, leading to inflammatory cell infiltration in the heart, thereby contributing to adverse cardiac remodelling. [154] [155] [156] Multiple preclinical studies have suggested a role of insulin resistance in the pathogenesis of PAH. [157] [158] [159] Indeed, patients with PH and diabetes have higher right atrial pressure, as well as lower RV stroke volume and an increase in RV fibrosis, compared to patients with PAH alone. [160] [161] [162] In addition, a recent clinical study revealed that iPAH patients have glucose intolerance and an impaired ability to produce insulin following a glucose challenge. Pancreatic b-cell dysfunction in iPAH is associated with circulating CXCL- 10. 163 Altogether, the vicious cycle between inflammatory responses and metabolic dysregulation may play a role in linking systemic inflammation and inflammation in RV. However, the link between inflammation, metabolic dysregulation and RV dysfunction in PAH needs to be further studied.
Anti-inflammatory therapies
The biological effects of pro-inflammatory cytokines can be antagonized by so-called 'biological response modifiers', which bind and/or neutralize soluble cytokines such as IL-1b and TNF-a. Although none of these antiinflammatory therapies have been approved for clinical use to treat left HF, several therapies have been explored in phase II-III clinical trials.
IL-1 blockade in HF
IL-1 is a major pro-inflammatory cytokine and in the complex processes involved in innate immune responses IL-1 acts as a 'gatekeeper of inflammation'. 164 IL-1 has been found to contribute to pulmonary arterial remodelling in PAH. 4 IL-1b is the main circulating form of IL-1, responsible for systemic effects. 14 Among HF patients, a correlation has been found between declining functional class and increasing levels of IL-1b. 165 Similarly in PAH patients, IL-1b serum levels are also increased and these levels correlate with a worse outcome. 33 Several clinical trials were conducted to assess the effects of IL-1 blockade with anakinra on HF patients. In AIR-HF trial on seven patients with HF with reduced EF (HFrEF), anakinra treatment for 14 days reduced the plasma concentrations of IL-1b, C-reactive protein, and IL-6, as well as improved aerobic exercise capacity. 166 In the D-HART pilot trial with 12
HFpEF patients, anakinra treatment for 14 days also reduced the systemic inflammatory response and led to a significant improvement in aerobic exercise capacity. 167 A more recent pilot trial of anakinra on acute decompensated HF [ADHF study (NCT02173548)] with 30 HFrEF patients showed reduced systemic inflammatory responses and no adverse clinical events. 168 Another study in 60 patients with recently decompensated
HFrEF [RED-HART study (NCT01936909)] treatment with anakinra for 12 weeks resulted in a reduction of systemic inflammation, improvement in peak aerobic capacity and a trend towards reduce hospital readmission for HF at 6 months.
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TNF-a blockade
TNF-a has been recognized as a part of the innate immune system response to different forms of stress, which can be initiated independently from a specific antigen and use pattern recognition receptors. TNF-a stimulates NF-jB and increases the expression of genes required to control infection and injury. 92 In HF patients, TNF-a has been shown to be paradoxically increased in serum and the elevated level of serum TNF-a correlates with high mortality. 171 In PAH patients, elevated levels of serum TNF-a have also been found, even though no correlation was found between TNF-a levels and survival. 33 While TNF antagonism was beneficial in experimental HF models, 92, 172 randomized trials of anti-TNF therapy in human HF failed to show benefit. In the ATTACH trial for patients with NYHA class III-IV, anti-TNF therapy with infliximab did not improve HF and infliximab in high dosage was associated with worsening of the clinical status. 173 The TNF antagonist etanercept had short-term beneficial effects in small early studies, but larger multicentre trials in NYHA classes II-IV HF patients failed to demonstrate a benefit on mortality or hospitalization. 174, 175 Additionally, it was also recognized that treatment with the available TNF-a antagonists may involve significant toxicity, e.g. stabilization of circulating TNF-a (etanercept), and induction of lysis of cells expressing transmembrane TNF-a (infliximab). 176, 177 Hence, TNF-a is not a viable therapeutic target in HF.
Other anti-inflammatory therapies
Cytokines can promote ET-1 expression, which mediates a variety of processes including vasoconstriction, fibrosis, hypertrophy and neurohormonal activation, and ET-1 promotes inflammatory responses in the heart. 40, [44] [45] [46] An anti-inflammatory action has been attributed to the dual endothelin receptor antagonist bosentan in PAH. 178 However, clinical trials using bosentan in HF have suggested no overall benefit. 179 The direct effect of bosentan on the RV in PAH continues to be debated. A double-blind controlled trial in PAH patients with WHO functional class III demonstrated that bosentan failed to improve RV ejection fraction. 180 One explanation is that ET-1 has positive inotropic effects on the myocardium and may preserve RV contractility in RV hypertrophy; as such, ET antagonists may potentially lead to RV dysfunction in some PAH patients. The ACE2-angiotensin-(1-7)-Mas axis is a potential new target for the treatment of PAH and HF. 181 Ang 1-7 can decrease myocardial levels of pro-inflammatory cytokines including TNF-a and IL-6, thus reducing cardiac inflammation. 182, 183 Ang 1-7 treatment has cardioprotective effects in experimental models of non-ischaemic and ischaemic cardiomyopathy. [182] [183] [184] [185] The serum level of Ang-(1-7) was found to be decreased in patients with congenital heart disease related PAH. 186 Ang-(1-7) administration had beneficial pulmonary effects in the MCT induced PH model, without adverse effects on systemic blood pressure. 187 The effect of Ang-(1-7) on RVF needs to be further studied.
Conclusion
Triggered by systemic as well as local stresses, PAH and right HF are associated with inflammatory activation. Inflammatory cell influx commonly exists in the failing RV from patients with SSc associated and HIV associated PAH patients. While a limited number of studies on RV tissues from end-stage idiopathic PAH patients showed little evidence of inflammatory activation in the RV, existing human and experimental data suggest a role for inflammation in the early response to severe pressure overload and in the transition from RV adaptation to failure. All forms of PAH are associated with increased circulating levels of cytokines that are known to have the potential to interfere with cardiac contractility and remodelling. Preclinical studies on cardiac inflammation all suggest that inflammation is key in the vicious circle that exists between RV and pulmonary arterial remodelling. The benefits from anti-inflammatory therapies on LVF are still unclear, and the negative outcome of some clinical trials over the last years has raised doubt on the role of inflammation in HF. However, compared with LVF, anti-inflammatory therapies may be more successful when applied in PAH-related RVF, since inflammation plays a dual role in the pathogenesis of both pulmonary artery remodelling and RVF.
